Antibody Humanization

A lot of monoclonal antibodies are produced in non-human species, most often in mice. However, these non-humanized antibodies can elicit an immunogenic response when administered to patients, as the human immune system can recognize the non-humanized antibodies as foreign. There are two effective ways to overcome this drawback:

• 

Creation of chimeric antibodies (non-human variable regions with human constant regions) can partially alleviate these problems

• 

Humanization of the antibody which involves transferring the antibody complementarity-determining regions (CDRs) into a proper human antibody framework while retaining its original affinity and specificity

LakePharma has employed an efficient platform for antibody humanization. The services include:

Sequence Analysis Generating human antibody variants Humanized variant analysis in antibody humanization

 

Key Highlights

 

T20 Score Analyzer

Using LakePharma's T20 Score Analyzer tool, users are able to calculate a monoclonal antibody humanness score from antibody variable region sequences. The T20 Score Analyzer clearly distinguishes human and non-human antibodies with excellent specificity.

 

Download Antibody Discovery brochure

 Download PEGS Presentation - Integrated Solutions for Antibody Discovery and Beyond  View webinar: Discovery of Potent, Functional mAbs using Hybridoma and Phage Display Platforms
     
Cat.# Service Name Timeline Size Price Quantity Request
24401 Humanization and affinity measurement 8-9 weeks TBD Request

1. Antibody sequence analysis and homology modeling of mAb 3D structure.

2. Identification of key positions supporting CDR loop structure and VH-VL interface.

3. Design humanized variants (3VH, 3VL).

4. Assess the humanness of humanized variants by T20 humanness score developed at LakePharma. [Sean H Gao, Kexin Huang, Hua Tu, and Adam S Adler. (2013) Monoclonal antibody humanness score and its applications. BMC Biotechnology, 13:55]

5. Construct and express nine humanized antibodies (each combination of three designed heavy chains and three designed light chains) as well as a chimeric version (rodent variable regions, human constant regions) at the 10 mL scale in CHO cells (TunaCHO™ Process).

6. Assess expression levels and measure affinity by Octet, or competitive binding and compare to chimeric.

1. Sequences of VL and VH

2. Antigen and assay for measuring binding and affinity

1. Study report, including sequences of the humanized antibodies

2. All remaining purified antibodies